Get Easy Health Digest™ in your inbox and don’t miss a thing when you subscribe today. Plus, get the free bonus report, Mother Nature’s Tips, Tricks and Remedies for Cholesterol, Blood Pressure & Blood Sugar as my way of saying welcome to the community!
Enhanced external counterpulsation (EECP) is non-invasive heart therapy that is truly a valid cardiovascular treatment for ischemic heart disease and congestive heart failure. Although developed more than 50 years ago, I’ll tell you most cardiologists, especially heart surgeons, are disinterested in EECP. It is, as they know, a strong alternative to bypass surgery.
EECP, in many cases, is paid for by Medicare and Blue Cross and is approved by the Food and Drug Administration. It costs about $5,000 to $12,000 (the price can vary greatly) versus $50,000 to $80,000 (or even more) for bypass surgery, which is also a much greater health risk.
EECP should be used as a first option before bypass surgery. At this point, such is unthinkable to conventional heart medicine, which runs on huge amounts of money.
The testimonials of patients with severe angina are full of the highest praise. I have talked to one extremely serious heart patient who called EECP a miracle. He was an invalid, yet now he’s back to life — even playing golf.
EECP improves coronary flow reserve significantly at rest and with increased exercise tolerance. The main, essential feature of the EECP mechanism is the development and recruitment of collateral arteries. Collateral, or new arteries, implies more circulation and less angina.
Yes, this is the spontaneous growth and development of brand-new arteries on and around the heart to supply new and improved blood flow and oxygen to the heart.
The heart patient knows only too well the benefits of vasodilatation and increased blood flow to the heart. Extra dilation of the coronary arteries plus added blood flow via the new collaterals means greatly improved quality of life for an extended period — maybe several years, as experience has shown.
The data suggests that EECP therapy not only improves myocardial perfusion (circulation), but also decreases cardiac workload.
Some patients who may be excluded are those who:
- Have had myocardial infarction in the preceding three months.
- Have had intervention in the preceding two weeks.
- Suffer unstable angina (i.e., high risk angina).
- Have been diagnosed with overt congestive heart failure
- Have left ventricular ejection fraction of less than 30 percent.
- Suffer significant valvular disease.
- Have blood pressure more than 180/100 mm Hg.
- Have had a permanent pacemaker or implantable cardioverter defibrillator.
- Have non-bypassed left main stenosis of more than 50 percent.
- Suffer severe peripheral vascular disease, phlebitis, deep vein thrombosis, etc.
- Have atrial fibrillation or frequent ventricular premature construction that would interfere with EECP triggering (i.e., your electrocardiogram has to be reliable enough for the machine to work).
Not So Limiting
All this may sound very limiting, but my personal interview was with a serious cardiac patient who did exceedingly well. He previously had 17 procedures from two bypass surgeries and many stents, etc. If you have any of these limitations named, I suggest you still pursue EECP evaluation by a cardiologist to make sure that you aren’t excluded. If your cardiologist is indifferent to EECP, then get another cardiologist.
My research reveals that EECP is the best possible therapy before bypass surgery or even as a preventive for everybody. Why not overhaul your vascular system before you have a problem, particularly if heart disease is in your family?
EECP, coupled with a steady oral chelation and nutritional protocol, could easily add many quality years to your life.
I have had this full treatment for seven weeks. I know that the results are significant, and I have no angina except during extra heavy work or exertion.
I hope that within a few years EECP therapy will become public knowledge and in wide use. This activity will trigger more research and the development of a far more sophisticated and efficient EECP. This is very exciting — except maybe not for the bypass surgery industry.